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OBJECTIVES: Antihypertensive medication and lifestyle modification are crucial
for adequate control of hypertension in the vast majority of patients with this
condition. Poor adherence to one or both of these treatment modalities, however,
oftentimes prevents achievement of goal blood pressure. The primary objective of
this studywas to examine predictors of receiving and adhering to antihypertensive
medication and lifestyle modification for the treatment of hypertension.
METHODS: This study included adult respondents from the 2009 Behavioral Risk
Factor Surveillance Systemwho reported being diagnosed by a health care provider
as having hypertension (n38,474). A multivariable logistic regression model was
estimated to identify independent predictors of receiving and taking antihyperten-
sive medications as prescribed, as well as receiving and adhering to a lifestyle
modification advise from a healthcare provider, including modification of eating
habits, physical exercise, reduction of alcohol consumption and salt intake. The
following potential predictors were examined: respondent’s sex, education, em-
ployment,marital status, health status, health insurance access, cigarette use, and
geographic location. RESULTS: Black and older (65 years) patients were more
likely to be advised by healthcare providers to take medications for manage-
ment of their hypertension compared to White and younger patients (O.R.1.71
and OR11.2, p0.003 and p0.0001 respectively). All minority patients (Black,
Native Americans, Asians, and Hispanics) were more likely to receive a recom-
mendation about low-sodium diet and reduction of alcohol consumption com-
pared to Whites (p0.001). With respect to adherence to medication manage-
ment and life-style modifications, minority patients appeared to be similar or
even more adherent than White patients after controlling for respondent
characteristics. CONCLUSIONS: Our results indicate demographic differences
with regards to adherence to therapeutic medication and lifestyle-modification for
treating hypertension which may, in part, be a consequence of differences in how
providers counsel and treat patients based on their socio-demographic character-
istics.
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PRESCRIBING PATTERNS OF ANTIHYPERTENSIVE MEDICATIONS AMONG
DIABETIC PATIENTS IN THE UNITED STATES
Mountford WK, Covington D
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OBJECTIVES: Risk of cardiovascular disease death is 2-4 times higher in diabetics
than non-diabetics, and control of hypertension reduces this risk by up to 50%.
While there are numerous drug classes available for hypertension treatment, the
American Diabetes Association (ADA) specifically recommends ACE inhibitors or
ARBs because they offer additional vascular benefits in diabetes. Further, the ADA
suggests that multi-drug therapy is usually required to achieve blood pressure
targets. The objective of this study is to examine the prescribing patterns of anti-
hypertensive medications among diabetics relative the ADA recommendations.
METHODS:Data from the 2008 National AmbulatoryMedical Care Survey (NAMCS)
was utilized to identify office visits involving diabetic patients. This nationally
representative sample of US physician-patient office visits utilizes a multi-staged
sampling technique to collect several demographic and clinical parameters on
patient visits as well as information on up to eight continuous or newly prescribed
medications. Diabetes was identified by a physician questionnaire regarding pres-
ence of patient comorbidities and medications were identified using US National
Drug Codes. RESULTS: Of the 28,741 office visits collected, 2,955 were among dia-
betic patients and 49.3% (n1,456) of the diabetic patients were prescribed at least
one antihypertensive medication. ACE inhibitors were the most frequently pre-
scribed (40.9%), followed by beta blockers (39.4%), diuretics (30.2%), and calcium
channel blockers (20.5%). ARBs were less frequently prescribed (20%). Over half
(51.9%) were prescribed 2 or more hypertensive medications. CONCLUSIONS:
Based on data from the National Ambulatory Medical Care Survey, it appears that
ADA recommendations for hypertensive therapy in diabetics are being followed
with regard to ACE inhibitors and polytherapy. ARBs, however, appear less com-
mon in the population with other antihypertensive classes being prescribed more
frequently. Future studies involving longitudinal data are needed to evaluate
trending in the adherence to ADA recommendations for hypertensive therapy.
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READMISSION RATES AMONG PATIENTS WITH ACUTE MYOCARDIAL
INFARCTION AND TREATED WITH ASPIRIN WITH OR WITHOUT CLOPIDOGREL
DURING HOSPITALIZATION
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OBJECTIVES: Readmission rates in the US following acute myocardial infarction
(AMI) remain high despite intensive medical therapy. This study evaluated the
association between antiplatelet therapy, aspirin  clopidogrel and the short and
long term readmission rates in patients whowere hospitalized for AMI.METHODS:
Patients with an index hospitalization for AMI in 2007–2009 and also received in-
hospital aspirin  clopidogrel were selected based on diagnoses and pharmacy
records from 122 hospitals in a US electronic medical record database (Cerner’s
Health Facts). Readmission for any reason or recurrent AMI within 30 days and 1
year following index AMI discharge was assessed based on hospital records. Mul-
tivariate logistic regressionwas used to estimate the association between readmis-
sion and in-hospital antiplatelet therapy, adjusted for age, gender, comorbidities,
AMI type, and coronary revascularization during index hospitalization. RESULTS:
Among 23,394 patients diagnosedwithAMI during index hospitalization (mean age
68.7 years; 58%male), 35% received aspirin alone and 65% received aspirin clopi-
dogrel in hospital. Patients on aspirin clopidogrel were younger, hadmore STEMI
diagnosis, higher rates for hypertension, dyslipidemia, diabetes, and PCI/stent
placement, but lower rates for atrial fibrillation, congestive heart failure, and cere-
brovascular disease than patients on aspirin alone (all p0.001). Patients who re-
ceived aspirin  clopidogrel had lower rates of readmission for any reason at 30
days (11.5% vs. 14.7%; adjusted odds ratio (OR)  0.89 [95% CI: 0.82, 0.97]) and at 1
year (33.2% vs. 37.3%; OR 1.06 [1.00, 1.13]) compared to aspirin alone. AMI-related
readmission rates were similar between in-hospital treatment regimens.
CONCLUSIONS: Both 30-day and 1-year readmission rates remain high post AMI
discharge, despite antiplatelet therapy using aspirin clopidogrel. In-hospital dual
antiplatelet therapy was associated with a reduction in short-term readmission
rate overall but not for long-term or recurrent AMI in this cohort.
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OBJECTIVES: To determine 30-day readmissions in patients with heart failure in
Arizona and to assess the association of sociodemographic characteristics, primary
payer, and case-mix risk adjustment with hospital readmissions. METHODS: The
2005 Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and
Utilization Project (HCUP) State Inpatient Database (SID) for Arizona was used. The
HCUP revisit files were utilized to identify 30-day same diagnosis-related group
(DRG) readmissions for heart failure and shock (DRG 127). Hospital dischargeswere
included if age 65 years with patient residence in Arizona, and excluded if a
diagnosis was missing or was for end stage renal disease (ESRD). Index events to
determine readmissions were identified if there was no DRG for heart failure and
shock in the 30-days prior to admission. Readmissions were reported at both pa-
tient-level and index-event level. The association of sociodemographic, primary
payer, and case-mix risk adjustment (i.e., Charlson index) on patient level hospital
readmissions were evaluated using multivariate logistic regression. RESULTS: In
2005, some 7828 discharges among 6688 patients were included in the analysis. A
total of 6,333 discharges qualified as index events. Patients were, on average,
79.9(7.9) yearswith a Charlson index of 2.6(1.4). Themajoritywerewhite (83.5%)
and female (53.0%). Inpatient mortality was 3.1%(n210). Mean discharges were
1.2(0.5) per patient and ranged from 1-7. The proportion of patients with at least
one readmission was 5.3% (n355) and 5.6% (n355) of 6,333 index events resulted
in a readmission. From the multivariate regression, only the Charlson index was
significantly associated with patients with 1 readmission (OR1.3; 95%CI: 1.3,
1.4). CONCLUSIONS: This investigation of hospital readmissions for heart failure
suggests that case-mix risk adjustment is a significant predictor of 30-day readmis-
sion. To better understand the influence of index events future analysis will con-
sider predictors of readmissions with an index event level analysis.
PCV117
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OBJECTIVES: This survey investigated the implementation of hospital guidelines
for VTE prevention and protocols for VTE management/risk assessment and
thromboprophylaxis in hospitalized non-surgical, acutely-ill medical patients as
recommended by the American College of Chest Physicians.METHODS: As part of
a study of VTE in medically ill patients, identified from the HealthCore Integrated
Research Database, involving a random sample of 504 patients with medical
charts, a telephone survey of the 275 facilities in which these patients were hospi-
talizedwas conducted between June and September, 2011. An attemptwasmade to
contact Quality Management/Improvement (QM) coordinators at targeted institu-
tions. The survey consisted of a brief questionnaire (14 closed and 3 open-ended
questions) regarding the presence of hospital guidelines and risk assessment pro-
tocols. Results were summarized descriptively. RESULTS:We reached out to hos-
pital operators at all 275 facilities. Many of contacted persons, however, had diffi-
culty in identifying the QM department. Even when the correct department was
reached, approximately 90% of calls were routed directly to voicemail and repeated
calls (up to 3 calls at different times/days of week) were not returned.Wewere able
to directly speak with 30 (11%) QM coordinators, of whom, only 8 (27%) completed
the survey; 7 by telephone and 1 by email. Of the 8 (3%) hospitals that provided
responses, 76% had VTE-specific clinical guidance in place. Our low survey yield of
2.9% (8/275) is comparable with the response rate of 1.45% (21/1448) responding to
pertinent supplementary questions on VTE prevention in non-surgical patients
that were included in the survey conducted by the Joint Commission on Accredi-
tation for Healthcare Organizations (JCAHO) in 2009. CONCLUSIONS: QM depart-
ments in these hospitals are often unknown to hospital operators and QM coordi-
nators are generally hard to reach. Opportunities for improvement in the
implementation of VTE prophylaxis guidelines for hospitalized medically-ill pa-
tients exist.
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CHARACTERISTICS OF PATIENTS TREATED WITH THIENOPYRIDINES
FOLLOWING ACS-PCI
Nordstrom B1, Simeone JC1, Zhao Z2, Molife C2, Mccollam PL2, Ye X3, Effron MB2
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OBJECTIVES: To identify patient characteristics associated with filling a thien-
opyridine prescription (clopidogrel or prasugrel) following acute coronary syn-
drome (ACS) and percutaneous coronary intervention (PCI) in US health plans.
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METHODS:We identified patients hospitalized for ACS-PCIwith continuous enroll-
ment in MarketScan databases for  6 months before admission and 60 days after
discharge, without history of stroke or transient ischemic attack. Pharmacy dis-
pensing records were searched to determine the first, if any, thienopyridine dis-
pensed within 60 days after discharge. Demographic characteristics, medical and
treatment history during the 6 months prior to the hospitalization were compared
for patients filling prescriptions of clopidogrel, prasugrel, or neither. RESULTS: A
total of 39,953 patients were eligible for the analysis; 29,900 (74.8%) filled clopi-
dogrel prescriptions, 5,243 (13.1%) filled prasugrel prescriptions, and 4,810 (12.0%)
filled no thienopyridines within 60 days after ACS-PCI. Patients filling prasugrel
were younger (mean age 55.9 vs. 60.9, P0.0001), more likely to be male (78.9% vs.
72.2%, P0.0001), and from theMidwest (38.3% vs. 33.9%, P0.0001) comparedwith
clopidogrel users. Patients filling prasugrel had higher percentage of ST elevation
myocardial infarction (STEMI) during the hospitalization than clopidogrel (40.7%
vs. 33.3%, P0.0001). Charlson Comorbidity Index (CCI) was low (0-1) for more
prasugrel than clopidogrel users (85.9% vs. 80.2%, P0.0001); prevalence of many
comorbidities was also lower among prasugrel users. In contrast, patients with
no thienopyridine after ACS-PCI were older (mean age 62.2), more likely to have
high (2) CCI (25.5%, P0.0001), less likely to have STEMI (25.6%, P0.0001) and
a higher prevalence of many comorbidities than patients taking clopidogrel.
CONCLUSIONS: Patients filling no thienopyridine prescription following ACS-PCI
were older and had more comorbidities than patients filling clopidogrel prescrip-
tions. Patients filling prasugrel prescriptions tended to be younger and have fewer
comorbidities than thosewith clopidogrel, whichmay reflect lower bleeding risk of
this ACS-PCI population.
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ASSESSING THE EVIDENCE ASSIMILATION TIME FRAME: FROM TRIALS TO
TREATMENT GUIDELINES IN CARDIOVASCULAR DISEASE
Hanger M, Mahendraratnam N, Mitchell K
Avalere Health LLC, Washington, DC, USA
OBJECTIVES: The Institute of Medicine estimates that 17 years elapse between
phase III study completion and a new treatment’s full integration into clinical
practice. Recognizing that clinical practice guidelines (CPGs) are an important
source of information for clinicians as they integrate new treatments into routine
practice, we sought to understand the time it takes for CPGs to release recommen-
dations on novel therapies.METHODS:We conducted case analyses in CVD, a high
burden therapeutic area with numerous treatment options and well-established
guideline development processes. We selected 4 antithrombotic therapies intro-
duced over the past 15 years: ticagralor, dabigatran, prasugrel, and clopidogrel. For
each drug we captured key dates to assess the time interval between release of
registration trial data and inclusion in CPGs. The guidelines explored were the
leading US and EU references for the relevant indication, and “inclusion in CPGs”
referred to the presence of a class- or product-specific recommendation (October,
2011). RESULTS: Across 3 products, the interval from data release to CPG inclusion
ranged from 4 to 18 months (mean 25 months) in the United States, and 13 to 46
months (mean 29 months) in the EU. Limitations of the analysis include no dab-
igatran-relevant recommendations to date in the EU guidelines reviewed, and no
ticagrelor-relevant recommendations to date in the US guidelines reviewed. Addi-
tionally, ticagralor appeared in EU guidelines 2 months prior to regulatory
approval. CONCLUSIONS: Our observational analysis shows that the time it takes
for CPGs to incorporate new therapies varies, even within the same therapeutic
area and the same guideline developers. Future research will expand this inquiry
into other therapeutic areas and also explore various product- and market-level
factors that may affect time to CPG inclusion. While guidelines organizations work
to streamline review processes, manufacturers should improve their understand-
ing of revision timelines to maximize the impact of data release.
CARDIOVASCULAR DISORDERS – Research On Methods
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USING INTERNATIONAL HTA GUIDELINES TO INFORM UK HEALTH CARE
DECISION-MAKING: A CASE STUDY OF TICAGRELOR IN COMBINATION WITH
LOW-DOSE ASPIRIN FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
Dequen P1, Sutton AJ1, McGrath C2, Abrams K1
1University of Leicester, Leicester, UK, 2Pfizer Ltd., Tadworth, Surrey, UK
BACKGROUND: Several HTA agencies around the world have published compre-
hensive HTA guidelines to help authors adhere to the principles and methods of
HTA. Many have also embraced recent methodological developments in compar-
ative effectiveness research, such as indirect and mixed treatment comparisons,
and recommend their use when head-to-head evidence is not available. Differ-
ences exist, however, between these guidelines and how these are interpreted
especially in terms of evidential andmethodological requirements.OBJECTIVES:A
case study was conducted to evaluate the impact of different evidence synthesis
methods, as recommended by HTA agencies, on the effectiveness and cost-effec-
tiveness of new medicines in the UK.METHODS: Using a reconstructed economic
model based on the NICE technology appraisal for ticagrelor (TA236), different
evidence base andmeta-analysis methods were used, in accordance with country-
specific HTA guidelines and existing assessment reports (i.e. CADTH (Canada), CVZ
(The Netherlands), PBAC (Australia)), to estimate the relative effectiveness and
ICER of ticagrelor compared to clopidogrel and prasugrel for the treatment of acute
coronary syndromes. Differences in evidence identification and study selection,
evidence synthesis, and clinical effectiveness model inputs were evaluated.
PRELIMINARY RESULTS: Whilst CADTH and CVZ included a published indirect
comparison between ticagrelor and prasugrel in their evidence review; NICE re-
garded the use of indirect evidence as inappropriate and PBAC did not consider
prasugrel as a relevant comparator. Such differences in clinical evidence consid-
erations, and methods used call into question recent efforts to promote interna-
tional HTA harmonisation. In addition, the uncertainty in the results estimated in
our model demonstrated the importance of appropriately defining and measuring
(relative) efficacy inputs inHTA to ensure optimal health policies are implemented.
CONCLUSIONS: Since 2011, ticagrelor is recommended for use in the United King-
dom; however, the Canadian Expert Drug Advisory Committee recommended that
ticagrelor not be listed in publicly funded drug plans in Canada.
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AN ASSESSMENT OF THE MODIFIED RANKIN SCALE AS A STROKE OUTCOME
MEASURE IN ECONOMIC ANALYSES OF ACUTE ISCHEMIC STROKE OUTCOMES
Burton KR, Beaton DE
University of Toronto, Toronto, ON, Canada
OBJECTIVES: An effective measurement tool is required to assess the economic
effects of acute ischemic stroke (AIS) imaging interventions and to determine how
themagnitude of AIS-attributable impairment changes over time so that thesemay
be incorporated into economic analyses. The modified Rankin scale (mRS) is the
most prevalently used measure of AIS outcomes however it has generated skepti-
cism, concern and confusion regarding the results of stroke outcome studies. This
study assesses all clinimetric properties of the mRS and outlines improvement
opportunities.METHODS: ThemRS was analyzed using a set of clinimetric assess-
ment instruments including the Bombardier sensibility assessment tool and Bea-
ton responsiveness guidelines. Each clinimetric domain was evaluated, namely,
measure development; item generation; measure administration; sensibility; reli-
ability; validity; and responsiveness. RESULTS: The mRS displayed many short-
comings including: 1) vague definition of concept measured; 2) lack of item gener-
ation rigor; 3) compromised face validity; 4) no evidence of validity and reliability
among AIS patients; and 5) inadequate study of responsiveness due to arbitrary
choices of clinically important differences for comparison scales. CONCLUSIONS:
The mRS is a flawed instrument for estimating AIS outcomes. Minimally, high
quality, adequately powered de novo assessments of its validity, reliability and
responsiveness should be undertaken. Preferably, a new AIS outcome measure to
measure should be developed by following the detailed recommendations within
each of the clinimetric properties sections of this assessment. This ideal AIS out-
come measure could be applied to AIS outcome studies resulting in a facilitation,
rather than obfuscation, of efforts to reduce the burden of AIS.
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CAN MODERN PSYCHOMETRIC APPROACHES IMPROVE ROLE FUNCTIONING
ASSESSMENT IN ACUTE CORONARY SYNDROME PATIENTS? A PRELIMINARY
TRACE-CORE ANALYSIS
Anatchkova M1, Bjorner JB2
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Denmark
OBJECTIVES: Item response theory (IRT) combined with computer adaptive testing
(CAT) can improve assessment of self-reported measures by reducing measure-
ment error and respondent burden. We previously used IRT to develop an item
bank of health impact on role functioning (RF) in 3 areas (family, social, occupa-
tional).We tested the validity of a simulated 4-itemCATbased on 10 items fromour
previously-developed bank in acute coronary syndrome (ACS) patients and com-
pared its performance with 2 established SF-36 scales - role physical (RP) and role
emotional (RE).METHODS: Adults (n759) in Worcester, MA and Macon, GA were
interviewed during an ACS hospitalization for the TRACE-CORE (Transitions, Risk,
and Actions in Coronary Events: Center for Outcomes Research and Education)
study. Ten questions from the RF item bank were administered; we assessed their
construct validity using factor analysis. We produced a 4-item CAT using simula-
tions with the 10-item data. We compared score accuracy and ability to discrimi-
nate between groups based on levels of self-reported general health (SF-36), de-
pression (PHQ9) and anxiety (GAD7) for the 10 items, the CAT and the SF-36 role
scales. RESULTS: Average patient age was 61.111.6 years, with 64.8% men, 76%
non-Hispanicwhite, 13%African-American.We confirmed the construct validity of
the 10-bank items. The CAT improvedmeasurement precision and expandedmea-
surement range by 0.5 SD versus the SF36 RP. All measures discriminated across
levels of general health, depression, and anxiety (p 0.0001). The instruments
showed high agreement on the mean score for each subgroup, but the CAT scores
had lower SDs. Relative validity coefficients suggest that CAT discriminated better
than the SF36 RP and RE scales. CONCLUSIONS: Use of CAT improved assessment
accuracy and discrimination among pre-defined groups, suggesting modern psy-
chometric approach leads to practical advantages in assessment. Results will fur-
ther be validated with clinical criteria and predictive analysis.
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COMBINING ELECTRONIC HEALTH RECORDS AND PATIENT-REPORTED
INFORMATION IN THE UK: PRELIMINARY RESULTS FROM WASPS (WALES
SAIL  PRO STUDY)
Cascade E1, Ford D2, Nixon M3, Brooks C2, Heaven M2
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Consulting, Bracknell, Berkshire, UK
OBJECTIVES: As demand for real-world data increases, the need to adopt more
time and cost-efficient research methods will grow. Direct-to-patient studies (di-
rect patient recruitment without physician sites) are a novel, efficient approach
gaining proof in the United States. This study’s objective was to deploy a direct-to-
patient observational study in the UK including both patient-reported and elec-
tronic health data. METHODS: In October/November 2011, UK MediGuard.org
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